JP2007509058A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509058A5
JP2007509058A5 JP2006535367A JP2006535367A JP2007509058A5 JP 2007509058 A5 JP2007509058 A5 JP 2007509058A5 JP 2006535367 A JP2006535367 A JP 2006535367A JP 2006535367 A JP2006535367 A JP 2006535367A JP 2007509058 A5 JP2007509058 A5 JP 2007509058A5
Authority
JP
Japan
Prior art keywords
lower alkyl
cancer
compound
halo
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006535367A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509058A (ja
JP4755991B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/034179 external-priority patent/WO2005037273A1/en
Publication of JP2007509058A publication Critical patent/JP2007509058A/ja
Publication of JP2007509058A5 publication Critical patent/JP2007509058A5/ja
Application granted granted Critical
Publication of JP4755991B2 publication Critical patent/JP4755991B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006535367A 2003-10-16 2004-10-15 Ｒａｆキナーゼインヒビターとしての置換ベンゾアゾールおよびその使用 Expired - Fee Related JP4755991B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51196603P 2003-10-16 2003-10-16
US60/511,966 2003-10-16
PCT/US2004/034179 WO2005037273A1 (en) 2003-10-16 2004-10-15 Substituted benzazoles and use thereof as inhibitors of raf kinase

Publications (3)

Publication Number Publication Date
JP2007509058A JP2007509058A (ja) 2007-04-12
JP2007509058A5 true JP2007509058A5 (enExample) 2007-11-15
JP4755991B2 JP4755991B2 (ja) 2011-08-24

Family

ID=34465300

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006535367A Expired - Fee Related JP4755991B2 (ja) 2003-10-16 2004-10-15 Ｒａｆキナーゼインヒビターとしての置換ベンゾアゾールおよびその使用

Country Status (16)

Country Link
US (3) US7423150B2 (enExample)
EP (1) EP1682126B1 (enExample)
JP (1) JP4755991B2 (enExample)
KR (1) KR20060118472A (enExample)
CN (1) CN1889951A (enExample)
AT (1) ATE435015T1 (enExample)
AU (1) AU2004281151A1 (enExample)
CA (1) CA2542653A1 (enExample)
DE (1) DE602004021838D1 (enExample)
ES (1) ES2327418T3 (enExample)
IL (1) IL174965A0 (enExample)
MX (1) MXPA06004236A (enExample)
PL (1) PL1682126T3 (enExample)
PT (1) PT1682126E (enExample)
TW (1) TW200526208A (enExample)
WO (1) WO2005037273A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
EP1682126B1 (en) * 2003-10-16 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Substituted benzazoles and use thereof as inhibitors of raf kinase
WO2006124874A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
ATE476652T1 (de) * 2005-06-23 2010-08-15 Siemens Healthcare Diagnostics Quantitative assays für ras p21 in körperflüssigkeiten
PE20070335A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
CN102633783A (zh) * 2006-02-10 2012-08-15 转化技术制药公司 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
KR101464385B1 (ko) * 2006-04-19 2014-11-21 노파르티스 아게 ６-ｏ-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 ｃｓｆ-１ｒ 신호전달의 억제 방법
AU2008254425A1 (en) 2007-05-21 2008-11-27 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
AU2008256922B2 (en) * 2007-05-23 2011-07-28 Novartis Ag Raf inhibitors for the treatment of thyroid cancer
JP5352476B2 (ja) * 2007-06-05 2013-11-27 武田薬品工業株式会社 キナーゼ阻害剤としての二環式複素環化合物
JP5270553B2 (ja) * 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
WO2009028655A1 (ja) * 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
US20100261679A1 (en) * 2007-10-18 2010-10-14 James Sutton CSF-1R, Inhibitors, Compositions, and Methods of Use
CA2716947A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
WO2009111278A2 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
AR072657A1 (es) * 2008-02-29 2010-09-15 Genentech Inc Compuestos inhibidores de raf y metodos para su uso
US20110003859A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
US9540322B2 (en) * 2008-08-18 2017-01-10 Yale University MIF modulators
EP2399921B1 (en) 2008-12-01 2015-08-12 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
EP2545187B1 (en) 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
CA2824028A1 (en) * 2011-01-06 2012-07-12 Beta Pharma Canada Inc. Novel ureas for the treatment and prevention of cancer
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
EP2879677B1 (en) * 2012-07-28 2017-06-14 Calitor Sciences, LLC Substituted pyrazolone compounds and methods of use
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CA2971413A1 (en) 2014-12-16 2016-06-23 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
CN105949178B (zh) * 2015-03-09 2020-05-26 西格莱(苏州)生物医药有限公司 一种苯并咪唑类化合物、其制备方法、中间体及应用
CN107847494A (zh) 2015-06-10 2018-03-27 阿考温特科学股份有限公司 作为α7‑烟碱乙酰胆碱受体激动剂的氨基苯并异噁唑化合物
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
AU2017336074A1 (en) * 2016-09-30 2019-03-28 Epizyme, Inc. Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors
EP3579872A1 (en) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
WO2018195450A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
WO2018203219A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
CN108102093A (zh) * 2017-12-19 2018-06-01 中科院广州化学有限公司 一种含芴及吡啶基团的二胺单体及由其合成的聚酰亚胺
CA3086765A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
WO2020097396A1 (en) * 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
CA3156828A1 (en) 2019-10-03 2021-04-08 Dana-Farber Cancer Institute, Inc. Tricyclic kinase inhibitors and uses thereof
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2023009708A1 (en) * 2021-07-29 2023-02-02 Ajax Therapeutics, Inc. Heteroaryloxy triazolo- and imidazo-azines as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
CA3234638A1 (en) * 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung
EP1014953B1 (en) * 1997-03-05 2012-04-25 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
GB9711650D0 (en) 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6211177B1 (en) * 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2366932C (en) 1999-04-15 2009-08-25 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
ES2270867T3 (es) * 1999-09-23 2007-04-16 Astrazeneca Ab Compuestos de quinazolina terapeuticos.
EP1263753B1 (en) 2000-03-06 2004-05-06 SmithKline Beecham plc Imidazol derivatives as raf kinase inhibitors
EP1332131A2 (en) 2000-11-07 2003-08-06 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
US7238813B2 (en) 2000-11-29 2007-07-03 Smithkline Beecham Corporation Chemical compounds
US20030009034A1 (en) 2001-03-22 2003-01-09 Neil Wishart Transition metal mediated process
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
MXPA04009541A (es) * 2002-03-29 2005-01-25 Chiron Corp Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf.
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
EP1682126B1 (en) 2003-10-16 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Substituted benzazoles and use thereof as inhibitors of raf kinase

Similar Documents

Publication Publication Date Title
JP2007507428A5 (enExample)
JP2005529089A5 (enExample)
JP2007509059A5 (enExample)
JP5384611B2 (ja) 新規ヘテロ環式化合物およびそれらの使用
EP1678166B1 (en) Protein kinase inhibitors
JP6873145B2 (ja) ５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン
ES2456275T3 (es) Derivados de quinazolina moduladores de la quinasa JAK y su uso en métodos
CN114430740A (zh) Egfr抑制剂、组合物及其制备方法
JP2022125283A5 (enExample)
ZA200305619B (en) Substituted triazole diamine derivatives as kinase inhibitors.
JP2012501312A5 (enExample)
JP2010510319A5 (enExample)
ZA200603418B (en) Substituted benzazoles and use thereof as inhibitors of Raf kinase
JP5901634B2 (ja) キナゾリン化合物及びその使用方法
JP2013516393A5 (enExample)
CA2671982A1 (en) Methods of using mek inhibitors
WO2015015318A4 (en) Novel quinazolinones as bromodomain inhibitors
JP2008525463A5 (enExample)
JP2016522246A5 (enExample)
JP2010527373A5 (enExample)
RU2008141761A (ru) ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ
JP2012519179A5 (enExample)
AR074575A1 (es) Compuesto de benzoimidazol-pirimidin-aminopiridina, forma cristalina iii relacionada, formulacion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un cancer
RU2017118165A (ru) Ингибиторы энхансера гомолога 2 zestes
CZ304767B6 (cs) Substituovaný pyridin a pyridazin, farmaceutická kompozice s jeho obsahem a použití